Jupiter Topco’s Aurinia Pharmaceuticals AUPH Stock Holding History

Jupiter Topco’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10.2M	Buy	+602,195	New	+$9.62M	﹤0.01%	802

Other funds holding AUPH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Jupiter Topco's AUPH Position: Q2 2026 in Review

Jupiter Topco opened a new position in Aurinia Pharmaceuticals (AUPH) in Q2 2026: 602,195 shares worth $10.2M. The stake represents ﹤0.01% of the portfolio and ranks #802 among its holdings.

263 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

Jupiter Topco held 602,195 shares of Aurinia Pharmaceuticals worth $10.2M as of Q2 2026.
Aurinia Pharmaceuticals was a new Jupiter Topco position in Q2 2026.
Aurinia Pharmaceuticals made up ﹤0.01% of Jupiter Topco's portfolio in Q2 2026, its #802 holding.
263 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on Jupiter Topco's 13F filing for Q2 2026, filed 14 Aug 2026.